Skip to main content
[Preprint]. 2022 Jun 17:2022.06.14.22276393. [Version 2] doi: 10.1101/2022.06.14.22276393

Figure 2.

Figure 2.

SARS-CoV-2 infection, treatment with nirmatrelvir plus ritonavir, and hospitalization among study patients. Infections and treatment initiation included from January 1 to May 15, 2022. Hospitalizations included through May 29, 2022.